However, due to their robust nephroprotective effects, SGLT2 inhibitors are considered the preferred agents in patients with coexisting CKD, whereas GLP-1 RA may be particularly beneficial in individuals with concomitant obesity [70]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.